These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 3944273)

  • 1. Probucol inhibits oxidative modification of low density lipoprotein.
    Parthasarathy S; Young SG; Witztum JL; Pittman RC; Steinberg D
    J Clin Invest; 1986 Feb; 77(2):641-4. PubMed ID: 3944273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro.
    Regnström J; Walldius G; Carlson LA; Nilsson J
    Atherosclerosis; 1990 May; 82(1-2):43-51. PubMed ID: 2360919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of low density lipoprotein oxidation by thyronines and probucol.
    Hanna AN; Feller DR; Witiak DT; Newman HA
    Biochem Pharmacol; 1993 Feb; 45(3):753-62. PubMed ID: 8442772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo inhibition of foam cell development by probucol in Watanabe rabbits.
    Steinberg D; Parthasarathy S; Carew TE
    Am J Cardiol; 1988 Jul; 62(3):6B-12B. PubMed ID: 3394654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.
    Carew TE; Schwenke DC; Steinberg D
    Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7725-9. PubMed ID: 3478721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.
    Parthasarathy S
    J Clin Invest; 1992 May; 89(5):1618-21. PubMed ID: 1569200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
    Reaven PD; Parthasarathy S; Beltz WF; Witztum JL
    Arterioscler Thromb; 1992 Mar; 12(3):318-24. PubMed ID: 1547191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
    Kita T; Nagano Y; Yokode M; Ishii K; Kume N; Ooshima A; Yoshida H; Kawai C
    Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5928-31. PubMed ID: 3475709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the mechanism of action of probucol.
    Steinberg D
    Am J Cardiol; 1986 Jun; 57(16):16H-21H. PubMed ID: 3728306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipyridamole inhibits the oxidative modification of low density lipoprotein.
    Selley ML; Czeti AL; McGuiness JA; Ardlie NG
    Atherosclerosis; 1994 Nov; 111(1):91-7. PubMed ID: 7840817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyronines and probucol inhibition of human capillary endothelial cell-induced low density lipoprotein oxidation.
    Hanna AN; Titterington LC; Lantry LE; Stephens RE; Newman HA
    Biochem Pharmacol; 1995 Nov; 50(10):1627-33. PubMed ID: 7503765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of atherosclerotic progression in Watanabe rabbits by probucol.
    Kita T; Nagano Y; Yokode M; Ishii K; Kume N; Narumiya S; Kawai C
    Am J Cardiol; 1988 Jul; 62(3):13B-19B. PubMed ID: 3394648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions.
    Yamamoto A; Hara H; Takaichi S; Wakasugi J; Tomikawa M
    Am J Cardiol; 1988 Jul; 62(3):31B-36B. PubMed ID: 3394651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein.
    Parthasarathy S; Barnett J; Fong LG
    Biochim Biophys Acta; 1990 May; 1044(2):275-83. PubMed ID: 2344447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probucol protects low-density lipoproteins from in vitro and in vivo oxidation.
    Bittolo-Bon G; Cazzolato G; Avogaro P
    Pharmacol Res; 1994; 29(4):337-44. PubMed ID: 7971685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probucol does not affect lipoprotein metabolism in macrophages of Watanabe heritable hyperlipidemic rabbits.
    Nagano Y; Kita T; Yokode M; Ishii K; Kume N; Otani H; Arai H; Kawai C
    Arteriosclerosis; 1989; 9(4):453-61. PubMed ID: 2751475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of biologically modified low-density lipoprotein in atherosclerosis.
    Carew TE
    Am J Cardiol; 1989 Oct; 64(13):18G-22G. PubMed ID: 2679026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of oxidized lipoproteins in the pathogenesis of atherosclerosis.
    Kita T; Yokode M; Ishii K; Kume N; Nagano Y; Arai H; Otani H; Ueda Y; Hara S
    Clin Exp Pharmacol Physiol Suppl; 1992; 20():37-42. PubMed ID: 1446408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S 12340: a potent inhibitor of the oxidative modification of low-density lipoprotein in vitro and ex vivo in WHHL rabbits.
    Breugnot C; Privat S; Guillonneau C; Regnier G; Bouzom F; Vilaine JP; Lenaers A
    J Pharmacol Exp Ther; 1994 May; 269(2):515-20. PubMed ID: 8182520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenothiazines inhibit copper and endothelial cell-induced peroxidation of low density lipoprotein. A comparative study with probucol, butylated hydroxytoluene and vitamin E.
    Breugnot C; Mazière C; Salmon S; Auclair M; Santus R; Morlière P; Lenaers A; Mazière JC
    Biochem Pharmacol; 1990 Nov; 40(9):1975-80. PubMed ID: 2242028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.